The Challenges of 2022 for Biopharma

This week's season finale episode welcomes back some friends of the podcast – most of whom we interviewed on the show this year – to reflect on the past 12 months and give us their take on their key highlights. Hear Aliya Omer, Claire Gillis, Robert Grimm, Michele Manto, Paul Simms and Wendy White, unravel the past year in pharma, looking at everything from access challenges to organisational change to huge wins for marketing approaches and sharing some fascinating insights.

If you're interested in learning more about the topic areas discussed in this episode, check out the following content:

The impact of global instability https://www.emg-gold.com/_files/ugd/b8a9db_a8c25d06ae954bb98e0fa3448f259168.pdf

Behind the headlines of the Inflation Reduction Act https://www.emg-gold.com/post/behind-the-headlines-of-the-inflation-reduction-act

Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs

Embracing pharma's digital transformation https://www.emg-gold.com/post/embracing-pharma-s-digital-transformation

Elevating pharma's parental leave policies https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies